Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

DSpace Repository

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

Author: Moreau, P.; Joshua, D.; Chng, W-J; Palumbo, A.; Goldschmidt, H.; Hajek, R.; Facon, T.; Ludwig, H.; Pour, L.; Niesvizky, R.; Oriol, A.; Rosinol, L.; Suvorov, A.; Gaidano, G.; Pika, T.; Weisel, K.; Goranova-Marinova, V.; Gillenwater, H. H.; Mohamed, N.; Aggarwal, S.; Feng, S.; Dimopoulos, M. A.
Tübinger Autor(en):
Weisel, Katja
Published in: Leukemia (2017), Bd. 31, H. 1, S. 115-122
Verlagsangabe: Nature Publishing Group
Language: English
Full text: http://dx.doi.org/10.1038/leu.2016.186
ISSN: 1476-5551
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)